1 / 28

HIV Drug Resistance S urveillance 2004-2010

HIV Drug Resistance S urveillance 2004-2010. Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO, Geneva. July 22, 2012. www.who.in​t/ hiv /pub/​ drugresist ​ ance / repor ​t2012. Overview of WHO's Global HIVDR Strategy.

byron-simpson
Download Presentation

HIV Drug Resistance S urveillance 2004-2010

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV Drug Resistance Surveillance2004-2010 Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO, Geneva July 22, 2012

  2. www.who.in​t/hiv/pub/​drugresist​ance/repor​t2012

  3. Overview of WHO's Global HIVDR Strategy • Surveillance of Transmitted Drug Resistance • Surveillance of Acquired Drug Resistance • Monitoring of Early Warning Indicators

  4. TRANSMITTED HIV DRUG RESISTANCE

  5. Transmitted HIVDR (WHO surveys) Overview of Methods Method does not estimate point prevalence, but classifies levels in three categories*: Low prevalence <5% Moderate prevalence 5-15% High prevalence >15% Results not national or clinic-specific but apply to the geographic area surveyed within the country ARV-naïve populations likely to have been recently infected *M.Myatt et al. Antiviral Therapy 2008 D.Bennett et al. Antiviral Therapy 2008

  6. Transmitted HIVDR (WHO surveys) 2004-2010 • 72 surveys with results that could be classified as low, moderate or high to any drug class Note: based on the sub-set of 72 surveys whose HIVDR prevalence results could be classified as low, moderate or high for at least one drug class; areas surveyed differ between the two periods

  7. Transmitted HIVDR (WHO surveys) Surveys with Moderate Classification • 20 (out of 72 surveys) reported moderate levels of resistance to any drug class 2004 – 2010

  8. Transmitted HIVDR (WHO surveys) Geographical Distribution (pooled analysis) 82 surveys covering a total of 3588 recently-infected individuals, 2004-2010 Country reporting results from WHO surveys of transmitted HIV drug resistance, 2004–2010 No data available or not participating in the surveys Not applicable

  9. Transmitted HIVDR (WHO surveys) Estimates by year and region (pooled analysis) If you break down by drug class… Note: *test for trend, adjusted for region; Source: 82 WHO surveys covering 3588 recently-infected individuals

  10. Transmitted HIVDR (WHO surveys) Estimates by year, region and class of drug … estimated increase is only statistically significant for NNRTI in Africa. Note: *test for trend, adjusted for region; Source: 82 WHO surveys covering 3588 recently-infected individuals; all other regions omitted due to lack of statistical significance. Areas surveyed variec considerably among countries and over time..

  11. Transmitted HIVDR (WHO surveys)Mutation Prevalence (n=3588, pooled analysis from 82 surveys) Overall prevalence: 3.1% K103N or S: 0.8% D67N/G, K101E/P, Y181C and M184V: between 0.3 – 0.4% Note: drug resistance mutations as defined by WHO 2009 Surveillance Drug Resistance Mutation (SDRM) list

  12. Transmitted HIVDR (WHO surveys) Relationship between transmitted resistance to NNRTI and ART coverage Notes: p-value adjusted for region: 0.039. Odds-ratio = 1.49 (95% CI 1.07-2.08)

  13. Transmitted HIVDR - Conclusions More recent surveys reported higher average levels of transmitted resistance, particularly to NNRTI in the areas surveyed in the African region As expected, higher HIVDR prevalence is associated with higher ART coverage

  14. ACQUIRED HIV DRUG RESISTANCE

  15. Acquired HIVDR – WHO surveys Populations starting 1st-line ART at select clinics (naïve- and ARV-exposed) Objectives • To describe HIVDR in cohorts at start and 12 months after ART initiation • To estimate viral load suppression 12 months after ART initiation at the clinic level

  16. Acquired HIVDR (WHO surveys)40 surveys, 12 countries, 2006 – 2010

  17. Acquired HIVDR (WHO surveys) Mutation Prevalence at ART initiation (N = 5094) Any SDRM: 5% NNRTI: 3.7% NRTI: 1.4% NNRTI & NRTI: 0.6% Note: drug resistance mutations as defined by WHO 2009 Surveillance Drug Resistance Mutation (SDRM) list

  18. Acquired HIVDR (WHO surveys)HIVDR in Patients before ART Initiation (N = 5094) Note: "…" not available or applicable; select p-values could not be calculated due to collinearity, lack of data and/or variability

  19. Acquired HIVDR (WHO surveys)HIVDR in Patients Before ART Initiation (N = 5094) Note: "…" not available or applicable; select p-values could not be calculated due to collinearity, lack of data and/or variability

  20. Acquired HIVDR (WHO surveys) – Three 12-Month Outcomes (n=3834) • HIV drug resistance prevented: • - VL <1000 copies/ml • HIV drug resistance detected: • VL > 1000 copies/ml and HIVDR • HIV drug resistance possible: • - LTFU, stops and VL > 1000 copies/ml but no HIVDR observed

  21. Acquired HIVDR (WHO Surveys) Summary of 12-Month Outcomes (pooled, n=3834) aExcludes people who died or who were transferred to another antiretroviral therapy facility. bHIV drug resistance defined as a drug resistance prediction of low, intermediate or high level using the Stanford HIV database algorithm. Alternatively, if calculated based on the number of surveillance drug resistance mutations at endpoint, subregional, regional and overall proportions remain identical.

  22. Acquired HIVDR (WHO Surveys) Summary of 12-Month Outcomes (pooled, n=3834) 27.9% of patients failing therapy had no HIVDR 27.9% of patients failing therapy had no HIVDR

  23. Acquired HIVDR (WHO Surveys) Prevalence of Mutations in People Failing ART at 12 Months (pooled) (n=269) M184V: 58.7% K65R (10.4%) D67N (7.1%) T215 (multiple): 5.6% K219 (multiple): 4.8% ≥ 3 TAMs: 3.3% NNRTI NRTI NNRTI & NRTI

  24. Acquired HIVDR (WHO Surveys)Predicted HIVDR in people failing ART at 12 months (pooled) (n=269) Currently-recommended second-line regimens likely to be effective for the majority of patients failing first-line ART NRTIs commonly used in 2nd-line regimens * PI resistance was only observed for nelfinavir, resulting from the presence of multiple polymorphic mutations, especially in subtypes C, G and CRF02_AG. Nelfinavir resistance was never observed in specimens without predicted NRTI or NNRTI resistance. No drug resistance was predicted for any ritonavir-boosted PI. Based on the Stanford algorithm using resistance interpretation of "low-level" or higher.

  25. Acquired HIVDR (WHO Surveys) Summary of 12-Month Outcomes (pooled, n=3834)

  26. Acquired HIVDR (WHO Surveys) –Summary of Key 12-Month Outcomes (by clinic) Note: Possible drug resistance includes 75 patients with viral load greater than 1000 copies/ml at 12 months and no resistance, 13 who stopped antiretroviral therapy, 599 who were lost to follow-up, 34 with viral load greater than 1000 copies/ml at 12 months but with specimens failing to amplify and 1 with viral load greater than 1000 copies/ml at switch but failing to amplify PCR products

  27. Acquired HIVDR (WHO surveys) Conclusions AT ART INITIATION: 5% of individuals had any HIVDR-associated mutation Currently recommended first-line ART regimens will be effective for most people initiating treatment. • AT 12 MONTHS: • Of individuals initiating therapy: (i) 5.1% had any DR, (ii) 76.6% had no drug resistance, but (iii) 18.8% had possible DR • Of individuals failing therapy at 12 months: 72.1% had any DR (69.5% NNRTI, 62.5% NRTI, 59.9% NNRTI and NRTI) • Currently recommended second-line ART regimens will be effective for most people failing therapy if they were switched soon after virological failure

  28. CONCLUSIONS As ART roll out continues, increased rates of HIVDR may occur ART programs must be informed by routine programmatic evaluation to minimize first-line failure and HIVDR emergence and transmission Routine, standardized, population-based surveillance of HIVDR is imperative and must be in place to detect potential future increase of HIVDR in a timely manner Funders and national governments must step up to support and sustain a global approach to assessing HIVDR

More Related